BIOSECURE Act Aims to Reduce U.S. Biotech Reliance on China

New law seeks to address concerns over American dependence on Chinese biotechnology firms

Published on Feb. 22, 2026

Got story updates? Submit your updates here. ›

On December 18, 2025, the BIOSECURE Act was signed into law as part of the FY2026 National Defense Authorization Act. The act's purpose is to reduce U.S. operational dependence on Chinese biotechnology firms, which have become increasingly dominant in the global biotech supply chain.

Why it matters

The BIOSECURE Act is a response to growing concerns over America's reliance on Chinese biotechnology, which has raised national security and economic competitiveness issues. By reducing this dependency, the U.S. aims to bolster its own domestic biotech capabilities and supply chain resilience.

The details

The BIOSECURE Act includes provisions to incentivize U.S. biotech manufacturing, strengthen domestic research and development, and diversify the supply chain away from Chinese firms. However, some experts argue that the law may inadvertently deepen America's reliance on other foreign biotech sources, creating a new set of vulnerabilities.

  • The BIOSECURE Act was signed into law on December 18, 2025.
  • The act was included as part of the FY2026 National Defense Authorization Act.

The players

BIOSECURE Act

A new law aimed at reducing U.S. operational dependence on Chinese biotechnology firms.

Got photos? Submit your photos here. ›

What’s next

Experts will be closely monitoring the implementation and impact of the BIOSECURE Act in the coming years to assess whether it achieves its intended goals of strengthening American biotech capabilities and reducing reliance on China.

The takeaway

The BIOSECURE Act represents a significant policy shift to address concerns over America's biotech supply chain vulnerabilities, but its long-term effectiveness remains to be seen as the U.S. seeks to balance reducing one foreign dependency while potentially creating new ones.